Kyntra Bio (LTS:0IL8) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 09, 2026)


LTS:0IL8 Kyntra Bio Inc LTS:0IL8
50 GF Score
Price $7.45
GF Value $5.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Kyntra Bio's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

LTS:0IL8 vs TVGN, PSTV, GRDX: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Kyntra Bio's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyntra Bio Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Margin of Safety % (DCF Dividends Based) falls into.


LTS:0IL8
50GF Score
Kyntra Bio Inc LTS:0IL8
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for LTS:0IL8:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score

Get the complete analysis for LTS:0IL8

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price
$5.70
GF Value